小细胞肺癌,抗血管治疗系列研究汇总
全文概要
抗VEGF单抗
贝伐单抗
1. E3501、SALUTE、GOIRCAIFA FARM6PMFJM研究:EP+贝伐 vs EP,PFS延长
2. CALGB30306研究:IP+贝伐,主要终点未达到
抗血管生成融合蛋白
阿柏西普
3. NCT00828139研究:二线,拓扑替康+阿柏西普 vs 拓扑替康,铂类敏感PFS率改善
小分子酪氨酸激酶抑制剂
安罗替尼
4. ALTER1202研究:三线,安罗替尼 vs 安慰剂,OS明显延长;中国,获批三线
阿帕替尼
5. 两项研究:生存获益,但纳入病例数少
帕唑帕尼
6. Koinis等研究:铂类敏感患者有较好的客观反应率和疾病控制率
索拉菲尼
7. 一项研究:EP+索拉菲尼 vs EP,1年生存率25%
内源性血管生成抑制剂
恩度
8. 两项研究:EP+恩度 vs EP,生存略有获益
参考文献
[1]Horn L, Dahlberg SE, Sandler AB, et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol. 2009 Dec 10;27(35):6006-11. doi: 10.1200/JCO.2009.23.7545.
[2]Spigel DR, Townley PM, Waterhouse DM,et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol. 2011 Jun 1;29(16):2215-22. doi: 10.1200/JCO.2010.29.3423.
[3]Tiseo M, Boni L, Ambrosio F,et al. Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial. J Clin Oncol. 2017 Apr 20;35(12):1281-1287. doi: 10.1200/JCO.2016.69.4844.
[4]Ready NE, Dudek AZ, Pang HH, et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. J Clin Oncol. 2011 Nov 20;29(33):4436-41. doi: 10.1200/JCO.2011.35.6923.
[5]Allen JW, Moon J, Redman M, et al. Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol. 2014 Aug 10;32(23):2463-70. doi: 10.1200/JCO.2013.51.4109.
[6]ChengY,Wang Q,Li K,et al.Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial[J].J Thorac Oncol,2018,13(10):S351-S352.DOI:10.1016/j.jtho.2018.08.308.
[7]Xu Y, Huang Z, Lu H, et al. Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study. Br J Cancer. 2019 Oct;121(8):640-646. doi: 10.1038/s41416-019-0583-6.
[8]Luo H, Zhang L, Yang B, et al. A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer. Invest New Drugs. 2020 Feb;38(1):148-159. doi: 10.1007/s10637-019-00828-x.
[9]Sun JM, Lee KH, Kim BS, et al. Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). Br J Cancer. 2018 Mar 6;118(5):648-653. doi: 10.1038/bjc.2017.465.
[10]Koinis F, Agelaki S, Karavassilis V, et al. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group. Br J Cancer. 2017 Jun 27;117(1):8-14. doi: 10.1038/bjc.2017.137.
[11]Sharma N, Pennell N, Nickolich M, et al. Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. Invest New Drugs. 2014 Apr;32(2):362-8. doi: 10.1007/s10637-013-0061-6.
[12]Zhou ZT, Zhou FX, Wei Q, et al. Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol. 2011 Oct;68(4):1027-32. doi: 10.1007/s00280-011-1576-1.
[13]Lu S, Li L, Luo Y, et al. A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer. J Thorac Oncol. 2015 Jan;10(1):206-11. doi: 10.1097/JTO.0000000000000343.